Briggs Morrison - Feb 6, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Feb 6, 2023
Transactions value $
-$1,080,700
Form type
4
Date filed
2/8/2023, 03:49 PM
Previous filing
Feb 3, 2023
Next filing
Mar 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $337K +52.9K +296.33% $6.38 70.7K Feb 6, 2023 Direct
transaction SNDX Common Stock Sale -$1.42M -52.9K -74.77% $26.83 17.8K Feb 6, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -52.9K -100% $0.00* 0 Feb 6, 2023 Common Stock 52.9K $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 811,146 options to purchase shares of common stock that are vested and immediately exercisable and a total of 313,000 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $26.49 to $27.91.
F3 This option is fully vested.